Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C

Yuko Arima, Naoto Kawabe, Senju Hashimoto, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Kyoko Kobayashi, Naohiro Ichino, Keisuke Osakabe, Toru Nishikawa, Akihiko Okumura, Tetsuya Ishikawa, Kentaro Yoshioka

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Aim: To assess the regression of liver fibrosis after interferon (IFN) treatment in patients with chronic hepatitis C, liver stiffness (LS) was measured repeatedly and the factors associated with reduction of LS were assessed. Methods: LS was measured by transient elastography before treatment, at end of treatment (EOT), and 1 year and 2 years after EOT in 145 patients with chronic hepatitis C treated by IFN with or without ribavirin. Results: In the patients with sustained virological response (SVR) (. n = 93) and relapsers (. n = 28), LS significantly decreased at EOT (median, 5.4 [interquartile range, 4.0-8.6] kilopascals [kPa], . P < 0.0001 and 6.8 [4.5-8.9] kPa, . P = 0.0023) and 1 year after EOT (5.3 [4.2-7.0] kPa, . P < 0.0001 and 6.8 [4.5-9.3] kPa, . P = 0.0204) compared with baseline (8.0 [5.0-11.9] kPa and 10.6 [7.0-16.6] kPa). In SVR patients, LS significantly decreased 2 years after EOT (5.3 [4.1-6.3] kPa) compared with baseline (. P < 0.0001) and LS at EOT (. P = 0.0034). Two points or greater reduction of deduced stage at last LS measurement was observed in 78% of SVR patients, 59% of relapsers and 15% of patients with non-virological response whose pretreatment deduced stages were F3-F4. Fibrosis stage, hyaluronic acid levels, duration of treatment, response to treatment and alanine aminotransferase levels were associated with a 2-point or greater decrease of deduced fibrosis stage. Conclusion: IFN treatment reduced LS in SVR patients and relapsers. Significant reduction of LS is associated with milder fibrosis stage, lower hyaluronic acid levels, longer IFN treatment, virological response of SVR or relapse and higher alanine aminotransferase levels.

Original languageEnglish
Pages (from-to)383-392
Number of pages10
JournalHepatology Research
Volume40
Issue number4
DOIs
Publication statusPublished - 01-04-2010

Fingerprint

Chronic Hepatitis C
Interferons
Liver
Therapeutics
Fibrosis
Hyaluronic Acid
Alanine Transaminase
Elasticity Imaging Techniques
Ribavirin
Liver Cirrhosis
Recurrence

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

Arima, Y., Kawabe, N., Hashimoto, S., Harata, M., Nitta, Y., Murao, M., ... Yoshioka, K. (2010). Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. Hepatology Research, 40(4), 383-392. https://doi.org/10.1111/j.1872-034X.2009.00618.x
Arima, Yuko ; Kawabe, Naoto ; Hashimoto, Senju ; Harata, Masao ; Nitta, Yoshifumi ; Murao, Michihito ; Nakano, Takuji ; Shimazaki, Hiroaki ; Kobayashi, Kyoko ; Ichino, Naohiro ; Osakabe, Keisuke ; Nishikawa, Toru ; Okumura, Akihiko ; Ishikawa, Tetsuya ; Yoshioka, Kentaro. / Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. In: Hepatology Research. 2010 ; Vol. 40, No. 4. pp. 383-392.
@article{cc997b1a08c2445a8c02be8bcbe751f9,
title = "Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C",
abstract = "Aim: To assess the regression of liver fibrosis after interferon (IFN) treatment in patients with chronic hepatitis C, liver stiffness (LS) was measured repeatedly and the factors associated with reduction of LS were assessed. Methods: LS was measured by transient elastography before treatment, at end of treatment (EOT), and 1 year and 2 years after EOT in 145 patients with chronic hepatitis C treated by IFN with or without ribavirin. Results: In the patients with sustained virological response (SVR) (. n = 93) and relapsers (. n = 28), LS significantly decreased at EOT (median, 5.4 [interquartile range, 4.0-8.6] kilopascals [kPa], . P < 0.0001 and 6.8 [4.5-8.9] kPa, . P = 0.0023) and 1 year after EOT (5.3 [4.2-7.0] kPa, . P < 0.0001 and 6.8 [4.5-9.3] kPa, . P = 0.0204) compared with baseline (8.0 [5.0-11.9] kPa and 10.6 [7.0-16.6] kPa). In SVR patients, LS significantly decreased 2 years after EOT (5.3 [4.1-6.3] kPa) compared with baseline (. P < 0.0001) and LS at EOT (. P = 0.0034). Two points or greater reduction of deduced stage at last LS measurement was observed in 78{\%} of SVR patients, 59{\%} of relapsers and 15{\%} of patients with non-virological response whose pretreatment deduced stages were F3-F4. Fibrosis stage, hyaluronic acid levels, duration of treatment, response to treatment and alanine aminotransferase levels were associated with a 2-point or greater decrease of deduced fibrosis stage. Conclusion: IFN treatment reduced LS in SVR patients and relapsers. Significant reduction of LS is associated with milder fibrosis stage, lower hyaluronic acid levels, longer IFN treatment, virological response of SVR or relapse and higher alanine aminotransferase levels.",
author = "Yuko Arima and Naoto Kawabe and Senju Hashimoto and Masao Harata and Yoshifumi Nitta and Michihito Murao and Takuji Nakano and Hiroaki Shimazaki and Kyoko Kobayashi and Naohiro Ichino and Keisuke Osakabe and Toru Nishikawa and Akihiko Okumura and Tetsuya Ishikawa and Kentaro Yoshioka",
year = "2010",
month = "4",
day = "1",
doi = "10.1111/j.1872-034X.2009.00618.x",
language = "English",
volume = "40",
pages = "383--392",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "4",

}

Arima, Y, Kawabe, N, Hashimoto, S, Harata, M, Nitta, Y, Murao, M, Nakano, T, Shimazaki, H, Kobayashi, K, Ichino, N, Osakabe, K, Nishikawa, T, Okumura, A, Ishikawa, T & Yoshioka, K 2010, 'Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C', Hepatology Research, vol. 40, no. 4, pp. 383-392. https://doi.org/10.1111/j.1872-034X.2009.00618.x

Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C. / Arima, Yuko; Kawabe, Naoto; Hashimoto, Senju; Harata, Masao; Nitta, Yoshifumi; Murao, Michihito; Nakano, Takuji; Shimazaki, Hiroaki; Kobayashi, Kyoko; Ichino, Naohiro; Osakabe, Keisuke; Nishikawa, Toru; Okumura, Akihiko; Ishikawa, Tetsuya; Yoshioka, Kentaro.

In: Hepatology Research, Vol. 40, No. 4, 01.04.2010, p. 383-392.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C

AU - Arima, Yuko

AU - Kawabe, Naoto

AU - Hashimoto, Senju

AU - Harata, Masao

AU - Nitta, Yoshifumi

AU - Murao, Michihito

AU - Nakano, Takuji

AU - Shimazaki, Hiroaki

AU - Kobayashi, Kyoko

AU - Ichino, Naohiro

AU - Osakabe, Keisuke

AU - Nishikawa, Toru

AU - Okumura, Akihiko

AU - Ishikawa, Tetsuya

AU - Yoshioka, Kentaro

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Aim: To assess the regression of liver fibrosis after interferon (IFN) treatment in patients with chronic hepatitis C, liver stiffness (LS) was measured repeatedly and the factors associated with reduction of LS were assessed. Methods: LS was measured by transient elastography before treatment, at end of treatment (EOT), and 1 year and 2 years after EOT in 145 patients with chronic hepatitis C treated by IFN with or without ribavirin. Results: In the patients with sustained virological response (SVR) (. n = 93) and relapsers (. n = 28), LS significantly decreased at EOT (median, 5.4 [interquartile range, 4.0-8.6] kilopascals [kPa], . P < 0.0001 and 6.8 [4.5-8.9] kPa, . P = 0.0023) and 1 year after EOT (5.3 [4.2-7.0] kPa, . P < 0.0001 and 6.8 [4.5-9.3] kPa, . P = 0.0204) compared with baseline (8.0 [5.0-11.9] kPa and 10.6 [7.0-16.6] kPa). In SVR patients, LS significantly decreased 2 years after EOT (5.3 [4.1-6.3] kPa) compared with baseline (. P < 0.0001) and LS at EOT (. P = 0.0034). Two points or greater reduction of deduced stage at last LS measurement was observed in 78% of SVR patients, 59% of relapsers and 15% of patients with non-virological response whose pretreatment deduced stages were F3-F4. Fibrosis stage, hyaluronic acid levels, duration of treatment, response to treatment and alanine aminotransferase levels were associated with a 2-point or greater decrease of deduced fibrosis stage. Conclusion: IFN treatment reduced LS in SVR patients and relapsers. Significant reduction of LS is associated with milder fibrosis stage, lower hyaluronic acid levels, longer IFN treatment, virological response of SVR or relapse and higher alanine aminotransferase levels.

AB - Aim: To assess the regression of liver fibrosis after interferon (IFN) treatment in patients with chronic hepatitis C, liver stiffness (LS) was measured repeatedly and the factors associated with reduction of LS were assessed. Methods: LS was measured by transient elastography before treatment, at end of treatment (EOT), and 1 year and 2 years after EOT in 145 patients with chronic hepatitis C treated by IFN with or without ribavirin. Results: In the patients with sustained virological response (SVR) (. n = 93) and relapsers (. n = 28), LS significantly decreased at EOT (median, 5.4 [interquartile range, 4.0-8.6] kilopascals [kPa], . P < 0.0001 and 6.8 [4.5-8.9] kPa, . P = 0.0023) and 1 year after EOT (5.3 [4.2-7.0] kPa, . P < 0.0001 and 6.8 [4.5-9.3] kPa, . P = 0.0204) compared with baseline (8.0 [5.0-11.9] kPa and 10.6 [7.0-16.6] kPa). In SVR patients, LS significantly decreased 2 years after EOT (5.3 [4.1-6.3] kPa) compared with baseline (. P < 0.0001) and LS at EOT (. P = 0.0034). Two points or greater reduction of deduced stage at last LS measurement was observed in 78% of SVR patients, 59% of relapsers and 15% of patients with non-virological response whose pretreatment deduced stages were F3-F4. Fibrosis stage, hyaluronic acid levels, duration of treatment, response to treatment and alanine aminotransferase levels were associated with a 2-point or greater decrease of deduced fibrosis stage. Conclusion: IFN treatment reduced LS in SVR patients and relapsers. Significant reduction of LS is associated with milder fibrosis stage, lower hyaluronic acid levels, longer IFN treatment, virological response of SVR or relapse and higher alanine aminotransferase levels.

UR - http://www.scopus.com/inward/record.url?scp=77954369431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954369431&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2009.00618.x

DO - 10.1111/j.1872-034X.2009.00618.x

M3 - Article

VL - 40

SP - 383

EP - 392

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 4

ER -